SUBSCRIBE Blog with us: BLOGbiotech

GEN News Highlights

• Email
• Print
• Share
• More GEN News Highlights

Mar 25 2008, 12:04 PM EST

Ceragenix Hands Over Rights to Preclinical HIV Pipeline to FirstPoint Biotech

GEN News Highlights

Ceragenix Pharmaceuticals licensed a family of preclinical anti-HIV compounds to FirstPoint Biotech (FPBT). The transaction includes CSA-54 and other members of the Ceragenin™ group of candidates. Their systemic and topical use as drugs as well as incorporation into medical devices such as condoms, sprays, or gels will be assessed.

FPBT is responsible for clinical development and commercialization, while Ceragenix will provide consultation. The agreement provides for payment of milestone fees and royalties.

Researchers from Vanderbilt University found that CSA-54 potently inhibits HIV infection of primary human CD4+ T cells and was not toxic to epithelial cells at concentrations higher than those required to kill the virus, according to Ceragenix. The molecule also killed a wide range of HIV isolates and completely blocked genetically engineered HIV that enters the cells independent of cell-surface receptors, the company continues.

• Email
• Print
• Share
• More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:
	HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR